Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Brickell Biotech Inc (BBI) USD0.01

Sell:$1.15 Buy:$1.20 Change: $0.08 (6.35%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Sell:$1.15
Buy:$1.20
Change: $0.08 (6.35%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Sell:$1.15
Buy:$1.20
Change: $0.08 (6.35%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.

Contact details

Address:
5777 Central Ave Ste 102
BOULDER
80301-2870
United States
Telephone:
+1 (720) 5054755
Website:
https://brickellbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BBI
ISIN:
US10802T1051
Market cap:
$63.15 million
Shares in issue:
53.52 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Reginald Hardy
    Chairman of the Board, Co-Founder
  • Robert Brown
    Chief Executive Officer, Director
  • Andrew Sklawer
    Co-Founder, Chief Operating Officer, Secretary
  • Albert Marchio
    Chief Financial Officer
  • Jose Breton
    Chief Accounting Officer, Controller
  • David McAvoy
    Chief Compliance Officer, General Counsel, Assistant Secretary
  • Deepak Chadha
    Chief Research and Development Officer
  • Adam Levy
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.